Syndax Pharmaceuticals, Inc. (SNDX)

Every figure this model derived for SNDX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 187,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 547,860,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 675,039,000 AssetsCurrent 2026-06-30
current liabilities 99,677,000 LiabilitiesCurrent 2026-06-30
equity 15,099,000 StockholdersEquity 2026-06-30
interest expense 2,000 InterestExpenseNonoperating 2026-06-30
ocf -220,640,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 252,251,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 49,403,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up SNDX on one particular measure came for.

RatioValue
cash operating margin-55.01
current ratio6.77
current ratio reported6.77
deferred revenue growth0.0
dilution pct1.17
fcf margin-87.54
growth cv1.87
interest cover-97085.5
operating margin-76.98
owner earnings margin-107.13
revenue growth222.65
revenue growth per share218.91
rule of 40145.68
sbc pct revenue19.58

What to be careful about

What this model itself distrusts about SNDX's figures. Written by the derivation as it ran, not added afterwards.